Medicine Atlas

How Healing Is Practiced
Sign In
Text size
100%
Theme
Condition

Creutzfeldt-Jakob disease

Diseases of the Nervous System

Creutzfeldt-Jakob disease is an incurable, terminal, neurodegenerative disease belonging to the transmissible spongiform encephalopathy group of prion diseases. Misfolded prion proteins cause normal prion proteins in the brain to adopt the same abnormal shape in a self-perpetuating cycle, producing sponge-like tissue damage and neuronal death. Early signs include memory problems, behavioral changes, poor coordination and visual disturbances, progressing to dementia, involuntary movements, blindness, deafness, weakness and coma; about 70 percent of patients die within a year of diagnosis. Cases are sporadic (about 85 percent, cause unknown), familial (10 to 15 percent, inherited mutations) or acquired through contaminated medical procedures or tissue exposure; the disease was first described by German neurologist Hans Gerhard Creutzfeldt in 1920.

Facts
Classification
Body System
Nervous System 1
ICD-10 Chapter
I: Certain Infectious and Parasitic Diseases 2
First Described
1920 3
Sources
1. Creutzfeldt-Jakob disease (Wikipedia)
Lead: body system
Quote, Lead: body system
Creutzfeldt-Jakob disease (CJD) is an incurable, terminal, neurodegenerative disease belonging to the transmissible spongiform encephalopathy (TSE) group, also known as prion diseases.
View the Source
2. World Health Organization: ICD-10 Version:2019 - A81.0
World Health OrganizationICD-10 2019 category A81.0, Chapter I
Quote, ICD-10 2019 category A81.0, Chapter I
A81.0 Creutzfeldt-Jakob disease
View the Source
3. Creutzfeldt-Jakob disease (Wikipedia)
Lead section
Quote, Lead section
Creutzfeldt-Jakob disease (CJD) is an incurable, terminal, neurodegenerative disease belonging to the transmissible spongiform encephalopathy (TSE) group, also known as prion diseases.
View the Source
Wikidata: Creutzfeldt-Jakob disease
Wikidata Q49989, class allow-list match (w-wdresolver-0926)View the Source
Comments (0)
No comments yet. Be the first to share a thought.
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.